Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.05
HSIC's Cash-to-Debt is ranked lower than
98% of the 53 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.74 vs. HSIC: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
HSIC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.33 Max: N/A
Current: 0.05
Equity-to-Asset 0.41
HSIC's Equity-to-Asset is ranked higher than
53% of the 51 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.42 vs. HSIC: 0.41 )
Ranked among companies with meaningful Equity-to-Asset only.
HSIC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.51 Max: 0.67
Current: 0.41
0.21
0.67
Interest Coverage 21.81
HSIC's Interest Coverage is ranked higher than
60% of the 45 Companies
in the Global Medical Distribution industry.

( Industry Median: 13.37 vs. HSIC: 21.81 )
Ranked among companies with meaningful Interest Coverage only.
HSIC' s Interest Coverage Range Over the Past 10 Years
Min: 12.12  Med: 19.95 Max: 29.73
Current: 21.81
12.12
29.73
Piotroski F-Score: 4
Altman Z-Score: 5.02
Beneish M-Score: -2.51
WACC vs ROIC
8.33%
14.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 6.70
HSIC's Operating Margin % is ranked higher than
68% of the 53 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.78 vs. HSIC: 6.70 )
Ranked among companies with meaningful Operating Margin % only.
HSIC' s Operating Margin % Range Over the Past 10 Years
Min: 6.57  Med: 6.9 Max: 7.1
Current: 6.7
6.57
7.1
Net Margin % 4.53
HSIC's Net Margin % is ranked higher than
66% of the 53 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.65 vs. HSIC: 4.53 )
Ranked among companies with meaningful Net Margin % only.
HSIC' s Net Margin % Range Over the Past 10 Years
Min: 3.64  Med: 4.36 Max: 4.76
Current: 4.53
3.64
4.76
ROE % 18.62
HSIC's ROE % is ranked higher than
86% of the 51 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.33 vs. HSIC: 18.62 )
Ranked among companies with meaningful ROE % only.
HSIC' s ROE % Range Over the Past 10 Years
Min: 13.24  Med: 15.6 Max: 18.62
Current: 18.62
13.24
18.62
ROA % 7.98
HSIC's ROA % is ranked higher than
89% of the 53 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.93 vs. HSIC: 7.98 )
Ranked among companies with meaningful ROA % only.
HSIC' s ROA % Range Over the Past 10 Years
Min: 6.93  Med: 7.74 Max: 8.37
Current: 7.98
6.93
8.37
ROC (Joel Greenblatt) % 41.98
HSIC's ROC (Joel Greenblatt) % is ranked higher than
79% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 22.27 vs. HSIC: 41.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HSIC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 41.98  Med: 48.65 Max: 51.27
Current: 41.98
41.98
51.27
3-Year Revenue Growth Rate 9.00
HSIC's 3-Year Revenue Growth Rate is ranked higher than
57% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 6.40 vs. HSIC: 9.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HSIC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -12.6  Med: 9.25 Max: 262.3
Current: 9
-12.6
262.3
3-Year EBITDA Growth Rate 7.70
HSIC's 3-Year EBITDA Growth Rate is ranked lower than
59% of the 39 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.40 vs. HSIC: 7.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
HSIC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 3.7  Med: 11.5 Max: 38.9
Current: 7.7
3.7
38.9
3-Year EPS without NRI Growth Rate 7.90
HSIC's 3-Year EPS without NRI Growth Rate is ranked lower than
64% of the 36 Companies
in the Global Medical Distribution industry.

( Industry Median: 14.30 vs. HSIC: 7.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HSIC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -9.1  Med: 11.95 Max: 70.7
Current: 7.9
-9.1
70.7
GuruFocus has detected 4 Warning Signs with Henry Schein Inc $HSIC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HSIC's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

HSIC Guru Trades in Q2 2016

Ray Dalio 2,300 sh (New)
Jim Simons 56,906 sh (+38.77%)
Paul Tudor Jones 3,600 sh (+33.33%)
Ron Baron 378,609 sh (-0.03%)
Ken Fisher 496,793 sh (-0.54%)
Mario Gabelli 162,772 sh (-4.42%)
Jeremy Grantham 69,783 sh (-52.48%)
» More
Q3 2016

HSIC Guru Trades in Q3 2016

Steven Cohen 132,300 sh (New)
Ray Dalio Sold Out
Jim Simons Sold Out
Ron Baron 378,009 sh (-0.16%)
Mario Gabelli 159,022 sh (-2.30%)
Ken Fisher 479,454 sh (-3.49%)
Paul Tudor Jones 2,200 sh (-38.89%)
Jeremy Grantham 13,354 sh (-80.86%)
» More
Q4 2016

HSIC Guru Trades in Q4 2016

Joel Greenblatt 127,262 sh (New)
George Soros 2,200 sh (New)
Jim Simons 474,006 sh (New)
Steven Cohen 212,300 sh (+60.47%)
Paul Tudor Jones 2,300 sh (+4.55%)
Mario Gabelli 156,837 sh (-1.37%)
Ken Fisher 462,101 sh (-3.62%)
Ron Baron 359,595 sh (-4.87%)
Jeremy Grantham 7,431 sh (-44.35%)
» More
Q1 2017

HSIC Guru Trades in Q1 2017

Steven Cohen 322,763 sh (+52.03%)
Ron Baron 359,595 sh (unchged)
Jeremy Grantham Sold Out
George Soros Sold Out
Mario Gabelli 154,747 sh (-1.33%)
Ken Fisher 436,289 sh (-5.59%)
Jim Simons 313,606 sh (-33.84%)
Paul Tudor Jones 1,462 sh (-36.43%)
Joel Greenblatt 56,966 sh (-55.24%)
» More
» Details

Insider Trades

Latest Guru Trades with HSIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Distribution » Medical Distribution    NAICS: 423450    SIC: 5047
Compare:OTCPK:SHTDF, OTCPK:SHPMY, NYSE:ABC, NYSE:CAH, NAS:PDCO, NYSE:PBH, NYSE:OMI, NYSE:PMC, OTCPK:SNYR, OTCPK:FZMD, OTCPK:SCVM, NYSE:MCK » details
Traded in other countries:HS2.Germany,
Headquarter Location:USA
Henry Schein Inc is engaged in providing health care products and services to office-based dental, animal health and medical practitioners. It also provides its services to government, institutional health care clinics and other alternate care clinics.

Henry Schein distributes healthcare products in three primary categories--dental, animal health, and medical. The segments represent approximately 50%, 28%, and 20% of sales, respectively. Schein also offers office software products, in addition to technical, financial, and educational services. Approximately 35% of Schein's sales are outside the United States, and the company is based in Melville, New York.

Guru Investment Theses on Henry Schein Inc

Baron Funds Comments on Henry Schein Inc. - Oct 21, 2016

Shares of Henry Schein, Inc. (NASDAQ:HSIC), a global distributor of dental, medical, and animal health products, declined after reporting an unexpected slowdown in its North American dental and equipment sales. No specific reasons for the slowdown have emerged, and we believe that it is too early to extrapolate a trend. While performance in other divisions was solid, Schein’s earnings guidance was revised downward for the first time in several years. We are monitoring events but remain positive given, in our opinion, the company’s strong management, consistent performance, and large market opportunities.





From Baron Funds' Barron Asset Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Henry Schein Inc

Baron Funds Comments on Henry Schein Inc. Guru stock highlight
Shares of Henry Schein, Inc. (NASDAQ:HSIC), a global distributor of dental, medical, and animal health products, declined after reporting an unexpected slowdown in its North American dental and equipment sales. No specific reasons for the slowdown have emerged, and we believe that it is too early to extrapolate a trend. While performance in other divisions was solid, Schein’s earnings guidance was revised downward for the first time in several years. We are monitoring events but remain positive given, in our opinion, the company’s strong management, consistent performance, and large market opportunities. Read more...
Milestone Scientific, Inc. Announces Exclusive Distribution Agreement With Henry Schein, Inc.

Distribution Agreement Includes Dedicated Specialty Sales Force and Guaranteed Minimums
LIVINGSTON, NJ--(Marketwired - June 29, 2016) - Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that its Wand Dental, Inc. subsidiary has entered into a ten-year exclusive agreement with Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, for The Wand® STA® Computer Assisted Anesthesia System. Under the agreement, Henry Schein's Exclusive Products Sales Specialist Team, which is comprised of 25 sales representatives and supported by 900 field service representatives, will exclusively market and distribute The Wand® STA® Computer Assisted Anesthesia System, together with a select group of other devices, in the United States and Canada. To help educate its customers about the benefits of The Wand, Henry Schein is training specific members of its sales team to become experts in the features and benefits of the STA® system. The agreement has minimum purchase orders to maintain exclusivity in the third through tenth years, commencing at $2.75 million. Henry Schein will also continue to distribute the disposables for Wand Dental, Inc.'s legacy anesthesia system, The Compudent®.The Wand® STA® is the market-leading computer-controlled local anesthesia system, with over 50 million injections performed worldwide. The Wand® performs both traditional and newer dental anesthesia injections in a more effective and comfortable way for both the patient and the provider. The instrument utilizes patented technologies like computer-regulated flow rates, Dynamic Pressure Sensing (DPS®), and a uniquely ergonomic hand-piece to enable significant improvements over the traditional dental syringe, which has remained virtually unchanged for over 160 years.Gian Domenico Trombetta, CEO of Wand Dental, Inc. commented, "Following our success with Henry Schein earlier this year, we are excited to enter into this long-term, exclusive collaboration agreement. This agreement will enable us to partner with Henry Schein's field representatives and the company's unparalleled sales, marketing and distribution platform across North America. Meanwhile, we continue to expand our distribution partnerships globally and believe we have developed a highly cost effective and scalable platform to rapidly grow sales and profitability of our Wand Dental segment in the coming years."About Wand Dental, Inc.Headquartered in Livingston, NJ, Wand Dental, Inc. is a wholly-owned subsidiary of Milestone Scientific, Inc. and is engaged in the manufacture and sales of advanced computer-controlled drug delivery technologies to the global dental market. The company currently sells its award-winning products through a global distribution network serving North and South America, Asia, Africa, Europe and the Middle East.About Milestone Scientific Inc.Milestone Scientific Inc. (MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.Safe Harbor StatementThis press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2015. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: [email protected]
Tel: 212-671-1020



Read more...
Don’t Buy a 'Valuation High' Even well-regarded sources can give bad advice. Trust the numbers.
Imagine you just had the best week ever. Read more...

Ratios

vs
industry
vs
history
PE Ratio 27.35
HSIC's PE Ratio is ranked lower than
69% of the 42 Companies
in the Global Medical Distribution industry.

( Industry Median: 19.66 vs. HSIC: 27.35 )
Ranked among companies with meaningful PE Ratio only.
HSIC' s PE Ratio Range Over the Past 10 Years
Min: 12.02  Med: 22.44 Max: 37.08
Current: 27.35
12.02
37.08
Forward PE Ratio 24.69
HSIC's Forward PE Ratio is ranked lower than
100% of the 29 Companies
in the Global Medical Distribution industry.

( Industry Median: 16.08 vs. HSIC: 24.69 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 27.35
HSIC's PE Ratio without NRI is ranked lower than
67% of the 42 Companies
in the Global Medical Distribution industry.

( Industry Median: 20.98 vs. HSIC: 27.35 )
Ranked among companies with meaningful PE Ratio without NRI only.
HSIC' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.02  Med: 22 Max: 37.08
Current: 27.35
12.02
37.08
Price-to-Owner-Earnings 30.70
HSIC's Price-to-Owner-Earnings is ranked lower than
76% of the 29 Companies
in the Global Medical Distribution industry.

( Industry Median: 16.77 vs. HSIC: 30.70 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HSIC' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.72  Med: 22.85 Max: 38.42
Current: 30.7
10.72
38.42
PB Ratio 5.12
HSIC's PB Ratio is ranked lower than
87% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.47 vs. HSIC: 5.12 )
Ranked among companies with meaningful PB Ratio only.
HSIC' s PB Ratio Range Over the Past 10 Years
Min: 1.57  Med: 3.05 Max: 5.13
Current: 5.12
1.57
5.13
PS Ratio 1.23
HSIC's PS Ratio is ranked lower than
55% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.13 vs. HSIC: 1.23 )
Ranked among companies with meaningful PS Ratio only.
HSIC' s PS Ratio Range Over the Past 10 Years
Min: 0.48  Med: 0.9 Max: 1.35
Current: 1.23
0.48
1.35
Price-to-Free-Cash-Flow 25.98
HSIC's Price-to-Free-Cash-Flow is ranked lower than
73% of the 22 Companies
in the Global Medical Distribution industry.

( Industry Median: 16.56 vs. HSIC: 25.98 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HSIC' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.19  Med: 19.55 Max: 34.33
Current: 25.98
9.19
34.33
Price-to-Operating-Cash-Flow 22.93
HSIC's Price-to-Operating-Cash-Flow is ranked lower than
83% of the 23 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.03 vs. HSIC: 22.93 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HSIC' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.98  Med: 16.42 Max: 27.27
Current: 22.93
7.98
27.27
EV-to-EBIT 19.42
HSIC's EV-to-EBIT is ranked lower than
69% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 14.81 vs. HSIC: 19.42 )
Ranked among companies with meaningful EV-to-EBIT only.
HSIC' s EV-to-EBIT Range Over the Past 10 Years
Min: 6  Med: 12.4 Max: 20.7
Current: 19.42
6
20.7
EV-to-EBITDA 15.98
HSIC's EV-to-EBITDA is ranked lower than
71% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.78 vs. HSIC: 15.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
HSIC' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.2  Med: 10.6 Max: 17
Current: 15.98
5.2
17
PEG Ratio 4.30
HSIC's PEG Ratio is ranked lower than
67% of the 27 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.00 vs. HSIC: 4.30 )
Ranked among companies with meaningful PEG Ratio only.
HSIC' s PEG Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.09 Max: 4.36
Current: 4.3
0.56
4.36
Shiller PE Ratio 39.75
HSIC's Shiller PE Ratio is ranked lower than
67% of the 18 Companies
in the Global Medical Distribution industry.

( Industry Median: 30.82 vs. HSIC: 39.75 )
Ranked among companies with meaningful Shiller PE Ratio only.
HSIC' s Shiller PE Ratio Range Over the Past 10 Years
Min: 20.75  Med: 34.15 Max: 49.34
Current: 39.75
20.75
49.34
Current Ratio 1.48
HSIC's Current Ratio is ranked lower than
59% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.62 vs. HSIC: 1.48 )
Ranked among companies with meaningful Current Ratio only.
HSIC' s Current Ratio Range Over the Past 10 Years
Min: 1.45  Med: 2.12 Max: 2.98
Current: 1.48
1.45
2.98
Quick Ratio 0.77
HSIC's Quick Ratio is ranked lower than
82% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.07 vs. HSIC: 0.77 )
Ranked among companies with meaningful Quick Ratio only.
HSIC' s Quick Ratio Range Over the Past 10 Years
Min: 0.73  Med: 1.36 Max: 2.1
Current: 0.77
0.73
2.1
Days Inventory 66.19
HSIC's Days Inventory is ranked lower than
63% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 41.10 vs. HSIC: 66.19 )
Ranked among companies with meaningful Days Inventory only.
HSIC' s Days Inventory Range Over the Past 10 Years
Min: 54.28  Med: 60.27 Max: 68.85
Current: 66.19
54.28
68.85
Days Sales Outstanding 42.22
HSIC's Days Sales Outstanding is ranked higher than
72% of the 43 Companies
in the Global Medical Distribution industry.

( Industry Median: 53.92 vs. HSIC: 42.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
HSIC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.01  Med: 40.97 Max: 43.79
Current: 42.22
38.01
43.79
Days Payable 36.22
HSIC's Days Payable is ranked lower than
73% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 65.77 vs. HSIC: 36.22 )
Ranked among companies with meaningful Days Payable only.
HSIC' s Days Payable Range Over the Past 10 Years
Min: 36.22  Med: 42.46 Max: 48.19
Current: 36.22
36.22
48.19

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.50
HSIC's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 35 Companies
in the Global Medical Distribution industry.

( Industry Median: -1.40 vs. HSIC: 2.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HSIC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -30  Med: -0.65 Max: 49.5
Current: 2.5
-30
49.5

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 110.99
HSIC's Price-to-Tangible-Book is ranked lower than
98% of the 42 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.78 vs. HSIC: 110.99 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HSIC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.37  Med: 7.37 Max: 111.11
Current: 110.99
2.37
111.11
Price-to-Intrinsic-Value-Projected-FCF 1.71
HSIC's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
52% of the 27 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.59 vs. HSIC: 1.71 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HSIC' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.76  Med: 1.39 Max: 8.31
Current: 1.71
0.76
8.31
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.72
HSIC's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
67% of the 9 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.39 vs. HSIC: 1.72 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.38
HSIC's Price-to-Median-PS-Value is ranked lower than
77% of the 39 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.01 vs. HSIC: 1.38 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HSIC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27  Med: 0.87 Max: 1.47
Current: 1.38
0.27
1.47
Price-to-Peter-Lynch-Fair-Value 4.42
HSIC's Price-to-Peter-Lynch-Fair-Value is ranked lower than
92% of the 13 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.01 vs. HSIC: 4.42 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
HSIC' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.59  Med: 1.77 Max: 4.42
Current: 4.42
0.59
4.42
Price-to-Graham-Number 13.62
HSIC's Price-to-Graham-Number is ranked lower than
100% of the 30 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.77 vs. HSIC: 13.62 )
Ranked among companies with meaningful Price-to-Graham-Number only.
HSIC' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.09  Med: 3.01 Max: 23.53
Current: 13.62
1.09
23.53
Earnings Yield (Greenblatt) % 5.15
HSIC's Earnings Yield (Greenblatt) % is ranked lower than
69% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 6.75 vs. HSIC: 5.15 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HSIC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.8  Med: 8 Max: 16.7
Current: 5.15
4.8
16.7
Forward Rate of Return (Yacktman) % 11.60
HSIC's Forward Rate of Return (Yacktman) % is ranked higher than
56% of the 32 Companies
in the Global Medical Distribution industry.

( Industry Median: 9.60 vs. HSIC: 11.60 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
HSIC' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 10.5  Med: 14.8 Max: 28.4
Current: 11.6
10.5
28.4

More Statistics

Revenue (TTM) (Mil) $11,782
EPS (TTM) $ 6.57
Beta1.09
Short Percentage of Float3.10%
52-Week Range $146.23 - 183.00
Shares Outstanding (Mil)79.33

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 12,212 12,907 13,646
EPS ($) 7.21 8.06 8.93
EPS without NRI ($) 7.21 8.06 8.93
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.35%
Dividends per Share ($) 2.41 2.68
» More Articles for NAS:HSIC

Headlines

Articles On GuruFocus.com
Henry Schein And Alpha Omega International Dental Fraternity Brief Capitol Hill Lawmakers On Oral He May 04 2017 
Henry Schein To Present At Two Conferences In May May 03 2017 
Henry Schein Completes Acquisition of Southern Anesthesia + Surgical May 02 2017 
Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Storms In The South An May 01 2017 
Henry Schein To Webcast First Quarter 2017 Conference Call On Tuesday, May 9, 2017 At 10:00 a.m. ET Apr 25 2017 
Henry Schein Announces New $750 Million Credit Facility Apr 19 2017 
Henry Schein Donates More Than $80,000 In Health Supplies And Equipment To Children's Aid Society Co Apr 10 2017 
Henry Schein Awards Henry Schein Cares Gold Medal to Guiding Eyes for the Blind for Excellence in Ex Mar 31 2017 
Baron Funds Comments on Henry Schein Inc. Oct 21 2016 
Companies Trading with Low Price-Sales Ratios Aug 18 2016 

More From Other Websites
ETFs with exposure to Henry Schein, Inc. : May 18, 2017 May 18 2017
Henry Schein, Inc. :HSIC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 17, 2017 May 17 2017
Edited Transcript of HSIC earnings conference call or presentation 9-May-17 2:00pm GMT May 14 2017
Henry Schein (HSIC) Tops Q1 Earnings, Reaffirms '17 View May 09 2017
Henry Schein beats Street 1Q forecasts May 09 2017
Henry Schein Reports Record First Quarter Financial Results May 09 2017
Medical Product Q1 Earnings Due on May 9: XRAY, HSIC & More May 08 2017
Henry Schein And Alpha Omega International Dental Fraternity Brief Capitol Hill Lawmakers On Oral... May 04 2017
[$$] Henry Schein Acquires Southern Anesthesia & Surgical From Beecken Petty May 03 2017
Henry Schein To Present At Two Conferences In May May 03 2017
Henry Schein Completes Acquisition of Southern Anesthesia + Surgical May 02 2017
Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Storms In The South... May 01 2017
Henry Schein, Inc. – Value Analysis (NASDAQ:HSIC) : April 28, 2017 Apr 28 2017
Henry Schein, Inc. breached its 50 day moving average in a Bullish Manner : HSIC-US : April 27, 2017 Apr 27 2017
Henry Schein To Webcast First Quarter 2017 Conference Call On Tuesday, May 9, 2017 At 10:00 a.m. ET Apr 25 2017
Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings? Apr 24 2017
Henry Schein Announces New $750 Million Credit Facility Apr 19 2017
Henry Schein Donates More Than $80,000 In Health Supplies And Equipment To Children's Aid Society... Apr 10 2017
Henry Schein, Inc. breached its 50 day moving average in a Bearish Manner : HSIC-US : April 6, 2017 Apr 06 2017
Henry Schein Awards Henry Schein Cares Gold Medal to Guiding Eyes for the Blind for Excellence in... Mar 29 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat